Combination treatment for advanced EGFR-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new experimental drug (called TQB2928) combined with a standard targeted therapy pill for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can help when standard EGFR inhibitors are no longer effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced non-small cell lung cancer that has spread or cannot be surgically removed.
- Your cancer has a specific change called an EGFR mutation, and you have already tried a standard EGFR targeted therapy pill (like erlotinib, gefitinib, osimertinib) and it stopped working.
- You are able to perform daily activities with little help (ECOG score 0 or 1) and are expected to live more than 3 months.
- Your major organs (liver, kidneys, heart, etc.) are working well enough to safely receive the study drugs.
- If you could become pregnant or father a child, you must agree to use birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
This trial tests combining two targeted therapies (an EGFR inhibitor and a HER2-targeted drug) for advanced lung cancer that has both an EGFR mutation and a HER2 change. The goal is to see if this combination works better than current treatments.
This study tests a combination of two targeted therapy pills (andamertinib and anlotinib) for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has progressed after taking a previous targeted therapy. The goal is to see if this new combination can stop the cancer from growing.
This study tests a new combination of two drugs (QL1706 and anlotinib) for people with advanced small cell lung cancer or squamous cell lung cancer who have already tried at least two earlier treatments. The goal is to see if this combination can help control the cancer when other options have stopped working.
Hear when a new Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.